Login to Your Account



Isis moves antisense drug into pivotal phase III in SMA

By Marie Powers
Staff Writer

Friday, August 1, 2014
Isis Pharmaceuticals Inc. advanced another candidate from its rare drug portfolio into phase III development, initiating a pivotal study of the antisense drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription